Rani Therapeutics Holdings Inc Class A

RANI | $6.49 -2.99% 49K

(0.0% 1d) (106.8% 1m) (45.8% 1y) (0.0% 2d) (0.3% 3d) (-5.4% 7d) (-52.46% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 170,677,609
https://www.ranitherapeutics.com
Sec Filling | Patents | 2021 employees

(US) Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs.

add to watch list Paper trade email alert is off

Press-releases

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 87.39% | O: 0.84% H: 0.0% C: 0.0%
year update therapeutics financial

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-15 (Crawled : 20:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| Email alert Add to watchlist
report year therapeutics financial results

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 91.69% | O: 0.57% H: 6.84% C: 5.13%
rt-111 antibody positive topline therapeutics results study

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
Published: 2023-12-14 (Crawled : 13:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 123.75% | O: 4.35% H: 3.85% C: -5.45%
preclinical therapeutics

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 250.26% | O: 2.88% H: 0.0% C: -3.31%
ranipill business expansion program technology therapeutics financial results growth

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 234.5% | O: 0.0% H: 1.0% C: -1.0%
ranipill study

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
Published: 2023-10-19 (Crawled : 20:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 231.19% | O: 10.4% H: 0.0% C: -10.76%
antibody preclinical therapeutics study

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
Published: 2023-10-12 (Crawled : 20:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 236.18% | O: 0.5% H: 1.5% C: -1.0%
rt-102 research meeting bone therapeutics

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 144.16% | O: 1.46% H: 4.32% C: -2.52%
rt-111 ranipill therapeutics study

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
Published: 2023-09-07 (Crawled : 20:00) - globenewswire.com
RANI | $6.49 -2.99% 49K

| 78.4% | O: 0.0% H: 2.13% C: -0.8%
drug preclinical therapeutics

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-035576	4	2024-03-23	2024-03-21	Buy	A	323500	323500
0000950170-24-035571	4	2024-03-23	2024-03-21	Buy	A	323500	323500